

Mats Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/93565/publications.pdf>

Version: 2024-02-01

25
papers

827
citations

777949

13
h-index

759306

22
g-index

26
all docs

26
docs citations

26
times ranked

1019
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE. <i>European Child and Adolescent Psychiatry</i> , 2023, 32, 63-74.	2.8	1
2	Monitoring medication response in ADHD: what can continuous performance tests tell us?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 291-299.	1.8	7
3	Deficits in attention, motor control and perception from childhood to age 30 years: prospective caseâ€“control study of outcome predictors. <i>BMJ Open</i> , 2022, 12, e054424.	0.8	1
4	Neurodevelopmental disorders and somatic diagnoses in a national cohort of children born before 24 weeks of gestation. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2022, 111, 1167-1175.	0.7	25
5	National cohort of infants born before 24 gestational weeks showed increased survival rates but no improvement in neonatal morbidity. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2022, 111, 1515-1525.	0.7	11
6	Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5â€“90 years. <i>Brain Communications</i> , 2022, 4, .	1.5	57
7	Paediatric Acute onset Neuropsychiatric Syndrome: Exploratory study finds no evidence of HLA class II association but high rate of autoimmunity in firstâ€“degree relatives. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, , .	0.7	5
8	Attention-deficit/hyperactivity disorder with developmental coordination disorder: 24-year follow-up of a population-based sample. <i>BMC Psychiatry</i> , 2021, 21, 161.	1.1	9
9	No neurochemical evidence of neuronal injury or glial activation in children with Paediatric Acute-onset Neuropsychiatric Syndrome. An explorative pilot study. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 800-804.	1.3	2
10	Anti-inflammatory, antibacterial and immunomodulatory treatment in children with symptoms corresponding to the research condition PANS (Pediatric Acute-onset Neuropsychiatric Syndrome): A systematic review. <i>PLoS ONE</i> , 2021, 16, e0253844.	1.1	10
11	Long-term medication for ADHD and development of cognitive functions in children and adolescents. <i>Journal of Psychiatric Research</i> , 2021, 142, 204-209.	1.5	6
12	Paediatric acute-onset neuropsychiatric syndrome in children and adolescents: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 175-180.	2.7	31
13	Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD). <i>Nutrition and Health</i> , 2018, 24, 279-284.	0.6	14
14	Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2018, 32, 455-467.	2.7	13
15	Growth and Sexual Maturation in a 2-year, Open-label Clinical Study of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD. <i>European Psychiatry</i> , 2017, 41, S130-S130.	0.1	0
16	Omega 3/6 fatty acids for reading in children: a randomized, doubleâ€“blind, placeboâ€“controlled trial in 9â€“yearâ€“old mainstream schoolchildren in Sweden. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2017, 58, 83-93.	3.1	25
17	Blood pressure and anthropometry in children treated with stimulants: a longitudinal cohort study with an individual approach. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 499-506.	1.0	11
18	Extendedâ€“release guanfacine hydrochloride in 6â€“17â€“year olds with ADHD: a randomisedâ€“withdrawal maintenance of efficacy study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2016, 57, 717-728.	3.1	26

#	ARTICLE	IF	CITATIONS
19	Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2014, 28, 1191-1203.	2.7	37
20	Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 1861-1872.	0.3	55
21	Review: little evidence that PUFA supplementation improves symptoms in ADHD. <i>Evidence-Based Mental Health</i> , 2013, 16, 12-12.	2.2	0
22	Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2012, 4, 199-204.	1.7	26
23	Attention-deficit/hyperactivity disorder with oppositional defiant disorder in Swedish children – an open study of collaborative problem solving. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2012, 101, 624-630.	0.7	14
24	Omega-3/Omega-6 Fatty Acids for Attention Deficit Hyperactivity Disorder. <i>Journal of Attention Disorders</i> , 2009, 12, 394-401.	1.5	168
25	Co-existing disorders in ADHD ? implications for diagnosis and intervention. <i>European Child and Adolescent Psychiatry</i> , 2004, 13, 180-92.	2.8	273